Skip to main content
SpringerLink
Log in

Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies

Update zur Behandlung fortgeschrittener Melanome: zielgerichtete Therapie mit kleinmolekularen Hemmstoffen, Immuntherapie und zukünftige Kombinationstherapien

  • main topic
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

Early stage melanomas can achieve remarkable outcomes with surgery alone, but stage IV metastatic melanoma requires significant intervention and has poor outcomes. Here we present evidence on the latest advances in melanoma treatment, discuss the scientific concepts behind new therapies, and analyze the potential of future treatment combinations.

Zusammenfassung

Frühstadien des Melanoms sind durch einfache Exzision meist heilbar, aber fortgeschrittene und metastasierende Melanome haben noch immer eine schlechte Prognose für die meisten Patienten. In diesem Beitrag präsentieren die Autoren die Evidenz moderner Melanomtherapien, diskutieren die verschiedenen Konzepte und analysieren mögliche Kombinationstherapien.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF. et al. SEER Cancer Statistics Review (CSR) 1975–2011. Bethesda: National Cancer Institute; 2014.

    Google Scholar 

  3. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62:357–68, 375–6, 381–2.

    CAS  PubMed  Google Scholar 

  4. Balch CM, Gershenwald JE, Soong S‑J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012;6:391–405.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118–25.

    Article  CAS  PubMed  Google Scholar 

  7. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66.

    Article  CAS  PubMed  Google Scholar 

  8. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823–30.

    Article  CAS  PubMed  Google Scholar 

  9. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. Melanoma immunotherapy. Cancer Biol Ther. 2014;15:665–74.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs. 2000;14(5):299–318.

    Article  CAS  PubMed  Google Scholar 

  11. Jarkowski A, Norris L, Trinh VA. Controversies in the management of advanced melanoma: “Gray” areas amid the “black and blue”. Ann Pharmacother. 2014;48:1456–68.

    Article  PubMed  Google Scholar 

  12. National Cancer Institute. Targeted cancer therapies 2014. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. Accessed 11 Nov 2014.

    Google Scholar 

  13. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.

    Article  CAS  PubMed  Google Scholar 

  14. Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med. 2013;11:202.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308.

    Article  CAS  PubMed  Google Scholar 

  16. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–9.

    CAS  PubMed  Google Scholar 

  17. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004;14:639–47.

    Article  CAS  PubMed  Google Scholar 

  18. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239–46.

    Article  PubMed  Google Scholar 

  19. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma – role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf. 2014;6:77–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.

    Article  CAS  PubMed  Google Scholar 

  21. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA. 2010;107:14903–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rahman MA, Salajegheh A, Smith RA, Lam AK-Y. BRAF inhibitors: from the laboratory to clinical trials. Crit Rev Oncol Hematol. 2014;90:220–32.

    Article  CAS  PubMed  Google Scholar 

  23. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. National Cancer Institute. FDA approval for Vemurafenib 2013. http://www.cancer.gov/cancertopics/druginfo/fda-vemurafenib. Accessed 11 Oct 2014.

    Google Scholar 

  25. Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A, et al. Updated overall survival (OS) results for BRIM‑3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol. 2012;30(Suppl):abstr 8502^, http://meetinglibrary.asco.org/content/97795-114. Accessed 11 Nov 2014.

    Google Scholar 

  26. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM‑3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436–44.

    Article  CAS  PubMed  Google Scholar 

  28. Hauschild A, Grob J‑J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.

    Article  CAS  PubMed  Google Scholar 

  29. Food and Drug Administration. Research C for DE and. Approved drugs – Dabrafenib 2014. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm354477.htm. Accessed 12 Oct 2014.

    Google Scholar 

  30. Hauschild A, Grobb J, Demidov L, Jouary T, Gutzmer R, Millward M, et al. An update on overall survival (os) and follow-on therapies in break-3, a phase iii, randomized trial: Dabrafenib (d) vs. Dacarbazine (dtic) in patients (pts) with Braf V600e mutation-positive metastatic melanoma (mm). Ann Oncol. 2014;25:iv378.

    Article  Google Scholar 

  31. Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:1121–9.

    Article  PubMed  Google Scholar 

  32. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600–mutant advanced melanoma treated with Vemurafenib. N Engl J Med. 2012;366:707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014;15:323–37.

    Article  PubMed  Google Scholar 

  34. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32:2248–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31:1767–74.

    Article  CAS  PubMed  Google Scholar 

  36. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93.

    Article  CAS  PubMed  Google Scholar 

  37. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94–109.

    Article  PubMed  Google Scholar 

  38. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B‑RAF(V600E) inhibition by RTK or N‑RAS upregulation. Nature. 2010;468:973–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Shi H, Moriceau G, Kong X, Lee M‑K, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B‑RAF inhibitor resistance. Nat Commun. 2012;3:724.

    Article  PubMed  Google Scholar 

  42. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–5.

    Article  CAS  PubMed  Google Scholar 

  45. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.

    Article  CAS  PubMed  Google Scholar 

  47. Food and Drug Administration. Research C for DE and. Approved drugs – Trametinib 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm354478.htm. Accessed 14 Oct 2014.

    Google Scholar 

  48. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482–9.

    Article  CAS  PubMed  Google Scholar 

  49. Grazia G, Penna I, Perotti V, Anichini A, Tassi E. Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol. 2014;45:929–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Food and Drug Administration. Research C for DE and. Approved drugs – Trametinib and Dabrafenib 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htm. Accessed 14 Oct 2014.

    Google Scholar 

  52. Long GV, Stroyakovsky DL, Gogas H, Levchenko E, de Braud F, Larkin JMG, et al. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol. 2014;32(S7):5–12, http://meetinglibrary.asco.org/content/128598-144. Accessed 14 Oct 2014.

    Google Scholar 

  53. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, et al. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71:1102–1109.e1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.

    Article  PubMed  Google Scholar 

  55. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.

    Article  PubMed  Google Scholar 

  56. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Food and Drug Administration. Press Announcements – FDA approves new treatment for a type of late-stage skin cancer 2011. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm. Accessed 24 Oct 2014.

    Google Scholar 

  58. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. doi:10.1200/jco.2014.56.2736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hamid O, Robert C, Daud A, Hodi FS, Hwu W‑J, Kefford R, et al. Safety and tumor responses with Lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.

    Article  CAS  PubMed  Google Scholar 

  61. Food and Drug Administration. Research C for DE and. Approved drugs – Pembrolizumab 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm. Accessed 25 Oct 2014.

    Google Scholar 

  62. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–9.

    Article  CAS  PubMed  Google Scholar 

  63. Weber JS, Minor DR, D’Angelo S, Hodi FS, Gutzmer R, Neyns B. et al. A phase 3 randomized, open-label study of Nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. ESMO Conference, Madrid. 2014.

    Book  Google Scholar 

  64. Food and Drug Administration. Press announcements – FDA approves Opdivo for advanced melanom 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm. Accessed 24 Dec 2014.

    Google Scholar 

  65. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–9.

    Article  CAS  PubMed  Google Scholar 

  66. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of Nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and Iipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol. 2014;32:5s, http://meetinglibrary.asco.org/content/126008-144. Accessed 6 Nov 2014.

    Article  Google Scholar 

  67. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus Ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943–55. doi:10.1016/s1470-2045(16)30126-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol. 2014;8:1140–58.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368:1365–6.

    Article  CAS  PubMed  Google Scholar 

  72. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120:1695–701.

    Article  CAS  PubMed  Google Scholar 

  73. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GCA, et al. Sequential treatment with Ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the Ipilimumab expanded access program. Cancer Invest. 2014;32:144–9.

    Article  CAS  PubMed  Google Scholar 

  74. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T‑cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386–94.

    Article  CAS  PubMed  Google Scholar 

  76. Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res. 2014;2:70–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Keck School of Medicine of USC (University of Southern California), Los Angeles, CA, USA

    Andrew Kwong

  2. Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy

    Martina Sanlorenzo

  3. Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Juchgasse 25, Vienna, 1030, Austria

    Klemens Rappersberger & Igor Vujic

  4. School of Medicine, Sigmund Freud University Vienna, Vienna, Austria

    Igor Vujic

Authors
  1. Andrew Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Sanlorenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Klemens Rappersberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Igor Vujic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Igor Vujic.

Ethics declarations

Conflict of interest

A. Kwong, M. Sanlorenzo, K. Rappersberger, and I. Vujic declare that they have no competing interests.

Additional information

K. Rappersberger and I. Vujic contributed equally to the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kwong, A., Sanlorenzo, M., Rappersberger, K. et al. Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wien Med Wochenschr 169, 314–322 (2019). https://doi.org/10.1007/s10354-016-0535-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-016-0535-1

Keywords

Schlüsselwörter

Search

Navigation